These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21381893)

  • 1. Adherence to single-pill combination versus multiple-pill combination lipid-modifying therapy among patients with mixed dyslipidemia in a managed care population.
    Kamat SA; Bullano MF; Chang CL; Gandhi SK; Cziraky MJ
    Curr Med Res Opin; 2011 May; 27(5):961-8. PubMed ID: 21381893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence.
    Balu S; Simko RJ; Quimbo RM; Cziraky MJ
    Curr Med Res Opin; 2009 Nov; 25(11):2765-75. PubMed ID: 19785511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy.
    Charland SL; Malone DC
    Curr Med Res Opin; 2010 Feb; 26(2):365-75. PubMed ID: 19995326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
    J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
    Feldman T; Davidson M; Shah A; Maccubbin D; Meehan A; Zakson M; Tribble D; Veltri E; Mitchel Y
    Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized comparative study of the effects of treatment with once-daily, niacin extended-release/lovastatin and with simvastatin on lipid profile and fibrinolytic parameters in Taiwan.
    Lin TH; Voon WC; Yen HW; Huang CH; Su HM; Lai WT; Sheu SH
    Kaohsiung J Med Sci; 2006 Jun; 22(6):257-65. PubMed ID: 16793562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
    Fazio S; Guyton JR; Polis AB; Adewale AJ; Tomassini JE; Ryan NW; Tershakovec AM
    Am J Cardiol; 2010 Feb; 105(4):487-94. PubMed ID: 20152243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [How sure is the combined lipid lowering?].
    Schäfer J
    MMW Fortschr Med; 2005 Jan; 147(1-2):56. PubMed ID: 15704576
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study.
    Rubenfire M;
    Am J Cardiol; 2004 Aug; 94(3):306-11. PubMed ID: 15276093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of ezetimibe with low doses of simvastatin in heart transplant recipients.
    Quarta CC; Potena L; Grigioni F; Scalone A; Magnani G; Coccolo F; Fallani F; Russo A; Branzi A
    J Heart Lung Transplant; 2008 Jun; 27(6):685-8. PubMed ID: 18503971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders.
    Vo AN; Kashyap ML
    Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1303-10. PubMed ID: 19018682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extended-release niacin.
    LaFleur J; Thompson CJ; Joish VN; Charland SL; Oderda GM; Brixner DI
    Ann Pharmacother; 2006; 40(7-8):1274-9. PubMed ID: 16849622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of niacin and simvastatin combination therapy.
    Bays H
    Am J Cardiol; 2008 Apr; 101(8A):3B-8B. PubMed ID: 18375239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg vs. placebo-simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolaemia.
    Patel JV; Hughes EA
    Int J Clin Pract; 2006 Aug; 60(8):914-21. PubMed ID: 16893434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. At sea with SEAS: the first clinical endpoint trial for ezetimibe, treatment of patients with mild to moderate aortic stenosis, ends with mixed results and more controversy.
    Hamilton-Craig I; Kostner K; Colquhoun D; Woodhouse S
    Heart Lung Circ; 2009 Oct; 18(5):343-6. PubMed ID: 19586799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study.
    Masana L; Mata P; Gagné C; Sirah W; Cho M; Johnson-Levonas AO; Meehan A; Troxell JK; Gumbiner B;
    Clin Ther; 2005 Feb; 27(2):174-84. PubMed ID: 15811480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin.
    Yiu KH; Cheung BM; Tse HF
    Expert Opin Investig Drugs; 2010 Mar; 19(3):437-49. PubMed ID: 20141348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome.
    Fazio S; Guyton JR; Lin J; Tomassini JE; Shah A; Tershakovec AM
    Diabetes Obes Metab; 2010 Nov; 12(11):983-93. PubMed ID: 20880345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simvastatin + ezetimibe: a combination with no proven advantages.
    Prescrire Int; 2007 Apr; 16(88):67. PubMed ID: 17460829
    [No Abstract]   [Full Text] [Related]  

  • 20. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
    Bays HE; Ose L; Fraser N; Tribble DL; Quinto K; Reyes R; Johnson-Levonas AO; Sapre A; Donahue SR;
    Clin Ther; 2004 Nov; 26(11):1758-73. PubMed ID: 15639688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.